Alprazolam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Alprazolam

Examples of brand names: Xanax [USA]; Tafil [DE]

ATC code: N05BA12

Main use (for orientation): Anxiety/panic

Documented research summary

No direct study with a quantified CBD/THC effect verified for the pair. Separate comparator arms and urine analyses without individual pair-specific values are not drug–drug interaction evidence.

Uncertainties and limitations

PMID40738618 full text/pair-specific result unresolved; no numerical effect derived from the general abstract. CYP3A plausibility remains theoretical.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Theoretical context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Theoretical plausibility; no verified clinical pair effect

Mechanism / drug context: Alprazolam: CYP3A4 and central nervous system depression.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Oral alprazolam as Xanax; active substance.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0068]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: XANAX (ALPRAZOLAM) TABLET [VIATRIS SPECIALTY LLC] [CA_L_D0068]

Source role [CA_P_30286443]: Scope distinction / context

Statement supported: Separate comparator arms, no combined CBD–alprazolam administration.

Source: Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. [CA_P_30286443]

Source role [CA_P_40738618]: Scope distinction / context

Statement supported: The urinary-metabolite abstract does not provide a quantitatively isolated alprazolam-pair effect.

Source: Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions. [CA_P_40738618]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0068] XANAX (ALPRAZOLAM) TABLET [VIATRIS SPECIALTY LLC]

Original source / bibliographic reference

Authors: Viatris Specialty LLC

Year: 2024

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_30286443] Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.

Original source / bibliographic reference

Authors: Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K.

Year: 2018

Source type: Research Support, Non-U.S. Gov't; Clinical Trial, Phase I; Randomized Controlled Trial; Journal Article

DOI: 10.1016/j.yebeh.2018.07.027

PMID: 30286443

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_40738618] Urinary metabolic ratio of pain management and substance abuse treatment drugs: Drug-drug interactions.

Original source / bibliographic reference

Authors: Cua A, Wickett E, Pesce AJ.

Year: 2025

Source type: Journal Article

DOI: 10.5055/jom.0907

PMID: 40738618

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility